CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT - USD ($) $ in Millions		Common Stock	Treasury Stock at Cost	Additional Paid-in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Total
Balances at beginning of period at Dec. 31, 2018		$ 0.9	$ (78.1)	$ 312.7	$ (6.5)	$ (510.8)	$ (281.8)
Balances at beginning of period (in shares) at Dec. 31, 2018		82,680,380
Increase (Decrease) in Stockholders' Deficit
Changes in accumulated other comprehensive loss, net					(3.1)		(3.1)
Stock-based compensation				2.1			2.1
Issuance of restricted stock, net (in shares)		1,702,482
Purchase of shares			(1.1)				(1.1)
Purchase of shares (in shares)		(108,937)
Net income						8.4	8.4
Balances at end of period at Mar. 31, 2019		$ 0.9	(79.2)	314.8	(9.6)	(502.4)	(275.5)
Balances at end of period (in shares) at Mar. 31, 2019		84,273,925
Balances at beginning of period at Dec. 31, 2018		$ 0.9	(78.1)	312.7	(6.5)	(510.8)	(281.8)
Balances at beginning of period (in shares) at Dec. 31, 2018		82,680,380
Increase (Decrease) in Stockholders' Deficit
Net income							18.1
Balances at end of period at Jun. 30, 2019	[1]	$ 0.9	(79.5)	317.6	(18.1)	(492.7)	(271.8)
Balances at end of period (in shares) at Jun. 30, 2019	[1]	84,473,673
Balances at beginning of period at Mar. 31, 2019		$ 0.9	(79.2)	314.8	(9.6)	(502.4)	(275.5)
Balances at beginning of period (in shares) at Mar. 31, 2019		84,273,925
Increase (Decrease) in Stockholders' Deficit
Changes in accumulated other comprehensive loss, net					(8.5)		(8.5)
Stock-based compensation				2.8			2.8
Issuance of restricted stock, net (in shares)		239,903
Purchase of shares			(0.3)				(0.3)
Purchase of shares (in shares)		(40,155)
Net income						9.7	9.7
Balances at end of period at Jun. 30, 2019	[1]	$ 0.9	(79.5)	317.6	(18.1)	(492.7)	(271.8)
Balances at end of period (in shares) at Jun. 30, 2019	[1]	84,473,673
Balances at beginning of period at Dec. 31, 2019		$ 0.9	(79.7)	322.8	(15.5)	(474.4)	$ (245.9)
Balances at beginning of period (in shares) at Dec. 31, 2019		84,103,108					84,103,108
Increase (Decrease) in Stockholders' Deficit
Changes in accumulated other comprehensive loss, net					(3.0)		$ (3.0)
Stock-based compensation				2.7			2.7
Issuance of restricted stock, net (in shares)		2,858,421
Purchase of shares			(0.7)				(0.7)
Purchase of shares (in shares)		(199,520)
Net income						0.1	0.1
Balances at end of period at Mar. 31, 2020		$ 0.9	(80.4)	325.5	(18.5)	(474.3)	(246.8)
Balances at end of period (in shares) at Mar. 31, 2020		86,762,009
Balances at beginning of period at Dec. 31, 2019		$ 0.9	(79.7)	322.8	(15.5)	(474.4)	$ (245.9)
Balances at beginning of period (in shares) at Dec. 31, 2019		84,103,108					84,103,108
Increase (Decrease) in Stockholders' Deficit
Net income							$ 2.3
Balances at end of period at Jun. 30, 2020		$ 0.9	(80.7)	328.5	(15.2)	(472.1)	$ (238.6)
Balances at end of period (in shares) at Jun. 30, 2020		87,064,765					87,064,765
Balances at beginning of period at Mar. 31, 2020		$ 0.9	(80.4)	325.5	(18.5)	(474.3)	$ (246.8)
Balances at beginning of period (in shares) at Mar. 31, 2020		86,762,009
Increase (Decrease) in Stockholders' Deficit
Changes in accumulated other comprehensive loss, net					3.3		3.3
Stock-based compensation				3.0			3.0
Issuance of restricted stock, net (in shares)		349,673
Purchase of shares			(0.3)				(0.3)
Purchase of shares (in shares)		(46,917)
Net income						2.2	2.2
Balances at end of period at Jun. 30, 2020		$ 0.9	$ (80.7)	$ 328.5	$ (15.2)	$ (472.1)	$ (238.6)
Balances at end of period (in shares) at Jun. 30, 2020		87,064,765					87,064,765

[1] Included in outstanding shares as of March 31, 2019 and June 30, 2019 are 3,703,649 and 3,601,021, respectively, of non-vested shares of restricted stock awards granted to employees and directors.